SynthesisFrontiers in immunology2025
Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Acute exacerbation in fibrotic interstitial lung disease: an international working group report.American journal of respiratory and critical care medicine · 2026Review
- Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease.Clinical reviews in allergy & immunology · 2026Review
- Prognostic value of HRCT-based risk stratification for acute/subacute progression in polymyositis/dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Interstitial lung disease (ILD), the main pulmonary manifestation of idiopathic inflammatory myopathy (IIM), frequently develops into rapidly progressive ILD (RP-ILD) with significantly worse prognosis. This meta-analysis identified risk and protective factors associated with developing RP-ILD in IIM patients. Methods: PubMed, Embase, Web of Science, and Scopus (up to October 2024) were searched, analyzing 21 retrospective studies (2,099 patients). Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were collected. Subgroup analysis was performed based on the RP-ILD definition. Sensitivity analysis and publication bias assessments (Egger's test and trim-and-fill method) were performed. Results: The associated risk factors for RP-ILD development in IIM patients included age (OR = 1.014, 95% CI: 1.002-1.025), clinically amyopathic dermatomyositis (OR = 3.023, 95% CI: 1.491-6.130), mechanic's hands (OR = 1.421, 95% CI: 1.054-1.915), fever (OR = 3.090, 95% CI: 1.933-4.939), pulmonary infection (OR = 2.610, 95% CI: 1.457-4.677), anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibodies (OR = 6.044, 95% CI: 4.331-8.435), anti-Ro-52 antibodies (OR = 2.425, 95% CI: 1.807-3.255), and elevated levels of ferritin (OR = 5.844, 95% CI: 4.121-8.287), lactate dehydrogenase (OR = 3.627, 95% CI: 2.406-5.466), erythrocyte sedimentation rate (OR = 1.598, 95% CI: 1.089-2.344), aspartate aminotransferase (OR = 2.666, 95% CI: 1.864-3.814), alanine transaminase (OR = 2.702, 95% CI: 1.737-4.201), and C-reactive protein (OR = 3.366, 95% CI: 2.149-5.274), whereas longer disease duration (OR = 0.790, 95% CI: 0.638-0.977) and dysphagia (OR = 0.773, 95% CI: 0.653-0.916) were potential protective factors. Conclusion: This meta-analysis of 21 retrospective studies identified potential risk and protective factors associated with RP-ILD development in IIM patients, providing a basis for early identification and management. Systematic Review Registration: https://inplasy.com/inplasy-2025-4-0059/, identifier INPLASY202540059.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.